Drug Discovery - Research & Development

Astellas and AI Proteins sign miniprotein therapeutics deal

AI Proteins has signed a research collaboration and licence agreement with Astellas Pharma’s affiliate Astellas Innovation Management for discovering and developing miniprotein therapeutics.

Sanofi and ScionxBio partner on mRNA therapies

Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology company ScionxBio to develop long-acting messenger ribonucleic acid (mRNA) therapies using the TERA platform.

Transcripta Bio, Mayo Clinic join force on ALS therapies

Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for amyotrophic lateral sclerosis (ALS).

Pfizer partners with Enodia Therapeutics in $500m drug deal

Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.

Southern Research secures NIH funding for drug testing hub

Southern Research has secured an $8m grant from the US National Institutes of Health (NIH) to establish a national shared-use biomedical facility, the Translational Hub for Research, Innovation, Validation, and Excellence (THRIVE).

Perceptive, Nucleus partner to support radiopharmaceutical development

Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist radiopharmaceutical developers shift from initial target validation through to clinical manufacturing.

Gilead Sciences signs five-year DevOps agreement with Cognizant

Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives.

AstraZeneca opens new R&D centre in Cambridge, US

AstraZeneca has opened a new global strategic research and development (R&D) facility in Massachusetts, US, as part of an investment of more than $1bn in the state.

BioMarin and Profluent partner on AI-designed enzyme therapies

BioMarin Pharmaceutical has entered a research collaboration with Profluent to design and optimise novel enzyme therapies for its drug development pipeline.